SCHEMBL850210

SCHEMBL850210

COc1cc(C)c(O)c2c1CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HPGD P15428 2/20 0.37
ALOX5 P09917 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
EGFR P00533 1/20 0.37
ADRA1A P35348 1/20 0.36
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 2/20 0.35
GAA P10253 2/20 0.35
CYP3A4 P08684 2/20 0.35
MEN1 O00255 1/20 0.35
XBP1 P17861 1/20 0.35
CYP2B6 P20813 1/20 0.35
MPI P34949 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9817570 0.78 ACHE (0.41) MAPTALDH1A1NPSR1ADRA1ACYP3A4
SCHEMBL21730241 0.76 CA1 (0.42) MAPTALDH1A1KDM4ELMNAGAA
SCHEMBL12023094 0.72 LMNA (0.39) MAPTALDH1A1NPSR1HPGDPTGS2
SCHEMBL9506919 0.71 ALOX5 (0.42) MAPTALDH1A1NPSR1ALOX5ADRA1A
SCHEMBL833885 0.71 ADRA1A (0.59) MAPTALDH1A1NPSR1HPGDADRA1A
SCHEMBL24407972 0.70 CYP3A4 (0.47) MAPTALDH1A1NPSR1HPGDALOX5
SCHEMBL5589677 0.70 CYP3A4 (0.52) MAPTALDH1A1NPSR1HPGDALOX5
SCHEMBL14283979 0.70 KDM4E (0.40) MAPTALDH1A1NPSR1HPGDKDM4E
SCHEMBL835276 0.69 ADRA1A (0.49) MAPTALDH1A1HPGDADRA1AKDM4E
SCHEMBL9843556 0.69 PTGS2 (0.39) MAPTHPGDALOX5PTGS2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378118-B2 Pyrazole-based thyroid receptor compounds TORRENT PHARMACEUTICALS LTD. (IN) 2013-02-19 US disclosed
US-20120202816-A1 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS, LTD. (IN) 2012-08-09 US disclosed
US-8143424-B2 Thyroid like compounds TORRENT PHARMACEUTICALS LTD. (IN) 2012-03-27 US disclosed
US-20100168110-A1 Novel Compounds TORRENT PHARMACEUTICALS LTD. (IN) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202816-A1 NOVEL COMPOUNDS TSHR, THRB, GPR119 MAPT 4782/4885ALDH1A1 1664/4885NPSR1 33/4885
US-20100168110-A1 Novel Compounds TSHR, THRB, GPR119 MAPT 4782/4885ALDH1A1 1664/4885NPSR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.